U of C joins trial of drug Metablox, hoped to treat severe COVID-19
Author of the article: Jason Herring Publishing date: Feb 13, 2021 • February 13, 2021 • 3 minute read • Dr. Dan Muruve (left), chief science officer of Arch Biopartners, and Dr. Alain Tremblay, professor at the University of Calgary's Cumming School of Medicine, are facilitating a Phase II human trial in Calgary for Metablok, a drug developed to combat organ inflammation often in severe cases of COVID-19. Photo by Submited Article content A made-in-Calgary drug that researchers hope can treat organ inflammation is now being tested on local COVID-19 patients. The Univer...